Citatuzumab bogatox - Eleven Biotherapeutics

Drug Profile

Citatuzumab bogatox - Eleven Biotherapeutics

Alternative Names: VB6-845; VB6-845d

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viventia Biotech
  • Developer Eleven Biotherapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 24 Nov 2017 Phase I development is underway for Solid tumours (Eleven Therapeutics pipeline, November 2017)
  • 24 Nov 2017 Citatuzumab bogatox is available for licensing as of 20 Nov 2017. http://www.elevenbio.com
  • 20 Nov 2017 Eleven Biotherapeutics plans to file an IND application for citatuzumab bogatox
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top